April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Candidate serum protein biomarkers of age-related macular degeneration (AMD)
Author Affiliations & Notes
  • Tammy M Martin
    Casey Eye Institute/Ophthalmology, Oregon Health & Science Univ, Portland, OR
    Devers Eye Institute, Legacy Research Institute, Portland, OR
  • Michael L Klein
    Casey Eye Institute/Ophthalmology, Oregon Health & Science Univ, Portland, OR
  • Phillip A Wilmarth
    Biochemistry & Molecular Biology, Oregon Health & Science Univ, Portland, OR
  • Frederick L Ferris
    National Eye Institute, National Institutes of Health, Bethesda, MD
  • Emily Y Chew
    National Eye Institute, National Institutes of Health, Bethesda, MD
  • Ashok P Reddy
    Proteomics Shared Resources, Oregon Health & Science Univ, Portland, OR
    Biochemistry & Molecular Biology, Oregon Health & Science Univ, Portland, OR
  • Larry L David
    Proteomics Shared Resources, Oregon Health & Science Univ, Portland, OR
    Biochemistry & Molecular Biology, Oregon Health & Science Univ, Portland, OR
  • Footnotes
    Commercial Relationships Tammy Martin, None; Michael Klein, None; Phillip Wilmarth, None; Frederick Ferris, None; Emily Chew, None; Ashok Reddy, None; Larry David, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 574. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tammy M Martin, Michael L Klein, Phillip A Wilmarth, Frederick L Ferris, Emily Y Chew, Ashok P Reddy, Larry L David; Candidate serum protein biomarkers of age-related macular degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2014;55(13):574.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine candidate serum protein biomarkers of age-related macular degeneration (AMD).

 
Methods
 

We analyzed pooled serum samples collected from subjects who had participated in the Age-Related Eye Disease Study. We pooled the samples into the following analytic groups, based upon the participants’ clinical AMD grade at the time of sample collection: No AMD, n=27; intermediate AMD (large drusen {LDr}), n=34; late AMD-neovascular (NV), n=34; and late AMD-geographic atrophy (GA), n=29. Samples were immunodepleted of the14 most abundant serum proteins using a Sigma IgY-14 column. One mg of protein/pooled sample was digested with trypsin in Rapigest, cation-exchange fractionated into 40 fractions, and analyzed using liquid chromatography/tandem mass spectrometry with a LTQ Velos ion trap mass spectrometer. Peptide and protein identification used SEQUEST and a UniProt database of human proteins amended with reversed decoy sequences to control false discovery. The total MS2 spectrum counts of peptides were used to measure differences in protein abundance between samples using a Chi-squared test and Z-score transformation of the data (p<0.01).

 
Results
 

Of the 717 identified proteins, 383 (53%) exceeded the minimum spectral count cutoff of 2.5. NV, GA, and LDr samples were more similar to each other than to No AMD controls. The number of differentially abundant proteins (AMD vs. control) was 47, 57 and 43 for NV, GA, and LDr respectively. Of these, 28 proteins passed differential criteria in all three disease groups vs. No AMD controls. We also observed differentially abundant proteins between AMD groups: 12 in NV vs. LDr, 14 in LDr vs. GA, and 12 in NV vs. GA. Several biological pathways were represented by differentially abundant proteins such as complement activation (including CR1, C4BPB, and SERPING1), lipid transport/regulation, retinol transport, oxidative enzymatic components and inflammatory mediators.

 
Conclusions
 

These data validate the concept that protein biomarkers reflect disease processes in AMD and suggest the feasibility of using signature biomarker patterns to identify disease-related parameters. Differentially abundant proteins between the NV, GA, and LDr, phenotypes may lead to a better understanding of the progression of AMD.

 
Keywords: 412 age-related macular degeneration • 663 proteomics • 609 neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×